Looking ahead to new biomarkers, clinical trials, and potential treatments for Alzheimer’s
NIA experts available to share context and insight on latest research shared at CTAD
WHAT: National Institute on Aging (NIA) experts will be available to further explain and analyze some of the latest research as presented at the 13th Annual International Conference on Clinical Trials for Alzheimer’s Disease (CTAD). This year’s digital event will include presentations from NIA researchers and NIA-funded scientists on topics such as anti-amyloid treatments, biomarkers, and new late-stage clinical trials in Alzheimer’s disease and related dementias.
“Biomarkers, in particular those using blood or plasma, are seen as a crucial step to help researchers and doctors screen people for early Alzheimer’s even before cognitive changes occur,” said Eliezer Masliah, M.D., director, NIA Division of Neuroscience. “In addition to featuring biomarker research, CTAD presentations highlight how NIA is funding trials at multiple stages across a diverse range of drug and mechanistic targets, including non-drug trials looking at nutrition, exercise, and combinations.”
NIA, part of the U.S. National Institutes of Health, is the single largest public funder of Alzheimer’s and related dementias research in the U.S. Through its multi-pronged approach, NIA currently is supporting more than 230 active clinical trials as well as innovative research to prime and redesign drug discovery for these devasting diseases.
NIA experts will be available for embargoed interviews beginning October 26 and during CTAD, November 4-7.
- Eliezer Masliah, M.D., director, Division of Neuroscience
- Partha Bhattacharyya, Ph.D., program officer, Division of Behavioral and Social Research
- Dimitrios Kapogiannis, M.D., investigator, Laboratory of Clinical Investigations, Intramural Research Program
- Kristina McLinden, Ph.D., program officer, Division of Neuroscience
- Laurie Ryan, Ph.D., chief, Clinical Interventions and Diagnostics Branch, Division of Neuroscience
- Molly Wagster, Ph.D., chief, Behavioral and Systems Neuroscience Branch, Division of Neuroscience
NIA-SUPPORTED PRESENTATION HIGHLIGHTS:
The following are just a few of the CTAD presentations with NIA involvement or support; please note, this research is embargoed until the start of the presentations:
Wednesday, November 4
- “The AHEAD 3-45 Study of BAN2401 in Preclinical Alzheimer’s Disease: Study Design and Initial Screening Results” 10 – 10:15 a.m. ET
AHEAD 3-45 is a public-private partnership involving the NIA-funded Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai. Dr. Ryan is available to describe the partnership as well as where this trial fits in with hundreds of other NIA-funded drug trials.
- “The LEADS (Longitudinal Early-onset Alzheimer’s Disease Study) Program: a new opportunity for therapeutic research” 11:30 – 11:50 a.m. ET
An NIA-funded consortium, LEADS will gather data to understand how and why approximately 5% of people with Alzheimer’s disease develop symptoms before age 65. Dr. Ryan is available to discuss how LEADS measures of a range of biomarkers is filling a gap in Alzheimer’s research.
Thursday, November 5
- “Effects of omega-3 (n-3) polyunsaturated fatty acids (PUFA) on cerebral white matter hyperintensities, medial temporal lobe atrophy and white matter integrity in older non-demented adults: A 3-year randomized-controlled phase 2 trial” 10:00 – 10:15 a.m. ET
This study is looking at the effect of a nutritional therapy and its ability to slow cognitive aging. Dr. Wagster is available to explain the mechanisms of cognitive change and trials looking to explore that.
- “Monoclonal antibodies against amyloid-β in Alzheimer’s disease. A meta-analysis of phase III clinical trials” 10:30 – 10:45 a.m. ET
This state-of-the-art analysis from the NIA Intramural Program supports amyloid as a target for drug development and anti-amyloid monoclonal antibodies as a treatment. Dr. Kapogiannis (with the presenter, NIA Visiting Fellow Konstantinos Avgerinos, M.D.) is available to discuss findings from this analysis, the clinical trial evidence, and explain monoclonal antibodies.
- “IMPACT-AD: A novel clinical trials training program” 12:30 – 12:45 p.m. ET
This on-demand, diversity-focused session describes IMPACT-AD — the Institute on Methods and Protocols for Advancement of Clinical Trials in Alzheimer’s Disease and related dementias. Drs. McLinden and Ryan are available to discuss the importance of educating and promoting diversity among research professionals and future principal investigators.
- “Pilot Randomized Controlled Trial of the Cognitive Effects of Aerobic Exercise in Alzheimer’s Disease” 2:45 – 3 p.m. ET
The NIA-funded Aerobic Exercise and Cognitive Training for MCI (ACT Trial) will compare the effects of cycling on a recumbent stationary bike and cognitive training alone and together in older adults with mild cognitive impairment (MCI). Dr. McLinden is available to discuss this and the more than 100 non-pharmacological trials.
Friday, November 6
- “Remote assessment of cognitive and clinical decline” 11:00 – 11:20 a.m. ET
COVID has made remote testing technology for research and care a priority. Dr. Bhattacharyya is available to discuss research into how technology can facilitate aging in place.
About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA’s Alzheimer’s Disease Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH…Turning Discovery Into Health®